First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
Executive Summary
The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.
You may also be interested in...
Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings
There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.